MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded Healthcare sector company. As of July 5, 2026, MBX trades at $57.80 with a market cap of $2.75B and a P/E ratio of -24.29. MBX moved +3.18% today. Year to date, MBX is +87.06%; over the trailing twelve months it is +368.77%. Its 52-week range spans $4.81 to $58.50. Analyst consensus is strong buy with an average price target of $74.75. Rallies surfaces MBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for MBX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $57.80 |
| Market Cap | $2.75B |
| P/E Ratio | -24.29 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $58.50 |
| 52-Week Low | $4.81 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-86.97M |
| Gross Margin | 0.00% |
9 analysts cover MBX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $74.75.